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Background: Variation in tumor biology in African-American (AA) and Caucasian (CAU) women with breast cancer
is poorly defined. Activated leukocyte cell adhesion molecule (ALCAM) is a bad prognostic factor of breast cancer
yet it has never being studied in the AA population. We tested the hypothesis that ALCAM expression would be
markedly lower in cases of AA breast cancer when compared to CAU.
Methods: Cases of breast cancer among AA (n = 78) and CAU (n = 95) women were studied. Immunohistochemical
staining was used to semi-quantitatively score ALCAM expression in tumor and adjacent non-tumor breast tissues.
Clinico-pathological characteristics including histological type, histological grade, tumor size, lymph node metastasis,
estrogen receptor (ER), progesterone receptor (PR), and HER2-neu status were abstracted, and their association with
ALCAM expression tested.
Results: Univariate analysis revealed that the level of ALCAM expression at intercellular junctions of primary tumors
correlates with histological grade (AA; p = 0.04, CUA; p = 0.02), ER status (AA; p = 0.0004, CAU; p = 0.0015), PR status
(AA; p = 0.002, CUA p = 0.034) and triple-negative tumor status (AA; p = 0.0002, CAU; p = 0.0006,) in both ethnic
groups. Multivariate analysis demonstrated that ethnicity contribute significantly to ALCAM expression after accounting
for basal-like subtype, age, histological grade, tumor size, and lymph node status. Compared to CAU tumors, the AA are
4 times more likely to have low ALCAM expression (p = 0.003).
Conclusions: Markedly low expression of ALCAM at sites of cell-cell contact in primary breast cancer tumors regardless
of differentiation, size and lymph node involvement may contribute to the more aggressive phenotype of breast cancer
among AA women.
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Breast cancer affects African-American (AA) women at a
lower frequency than Caucasian (CAU) women, yet pro-
gression of the tumor and mortality from the disease is
higher among AA [1]. This difference persists even after
taking into account access to care, tumor characteristics,
and treatments [2,3]. There are a few clear explanations
for these ethnic disparities [4]. The overwhelming majority
of studies aimed at understanding this disparity have* Correspondence: sfo2@pitt.edu
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unless otherwise stated.focused on socioeconomic and cultural differences, which
clearly have significant health consequences across a
broad spectrum of diseases, including cancer [2,5,6].
On the contrary, there is a paucity of studies on the
potential role of heterogeneity in tumor biology in the
health disparity of breast cancer in the US.
The discovery of molecular markers that influence prog-
nostic or treatment outcome may help to understand the
ethnic disparity in breast cancer in the US [7,8]. Adhesion
molecules tethered at sites of cell-cell contact intimately
influence cancer progression and the response to therapy,
and are therefore, candidate molecules for understanding
this disparity [9-12]. Activated leukocyte cell adhesion
molecule (ALCAM/CD166), is an immunoglobulin cell. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hematopoietic and epithelial cells [13-16]. We showed
previously that ALCAM is recruited to sites of cell-cell
contact in epithelium [17]. In a study of primary breast
cancer tissues and non-neoplastic mammary tissue from
the same mastectomies, we discovered that ALCAM
mRNA was lower in tumors from patients who had
metastases to regional lymph nodes and early mortality
[18]. Other studies confirmed that loss of ALCAM func-
tion, due to reduced expression and/or protein misloca-
tion is a bad prognostic marker in breast cancer [17-22].
ALCAM coalesces breast cancer cells together in homoty-
pic interactions thus preventing interactions with neigh-
boring endothelium, which may facilitate metastasis [23].
In support of this idea low ALCAM mRNA correlates
with the development of skeletal metastasis [24].
Despite the significance of ALCAM in breast cancer
this molecule has not previously been studied among
AA women. In the current study, we tested the hypoth-
esis that ALCAM expression is low in breast cancer tu-
mors of AA women, and that this phenomenon may
contribute to the more aggressive tumor phenotype in
this patient population. We found that ALCAM was re-
duced or completely absent at intercellular junctions of
most breast cancer tumors of AA women. On the con-
trary, the majority of tumors of CAU women had mod-
erate to high ALCAM expression. This ethnic disparity
was evident in tumors of similar histological grade, tumor
size and lymph node. Thus, loss of ALCAM may contrib-
ute to the more aggressive phenotype of breast cancer
among AA women.
Methods
Patients and tissue blocks
The study protocol was reviewed and approved by Emory
University’s Institutional Review Board (IRB) Committee.
The consent forms were not required for this study. Pa-
tients included in this study were self-reported as AA and
CAU diagnosed with invasive breast cancer. A total of 173
cases of invasive breast cancer (78 AA and 95 CAU) in
Emory University hospital or Grady Memorial Hospital
from 2007 to 2009 were studied. Tumor-related factors
(Histological type, histological grade, tumor size and nodal
status) were obtained from the independent abstraction of
pathology reports. Stage at diagnosis was defined using
American Joint Committee on Cancer Stage criteria that
are in use during the case ascertainment period (2007–
2009) [25]. Stage represents pathologic stage at the time
of the first diagnostic procedure confirming invasive
breast cancer and was divided into groups (I, II and III/IV).
Archived formalin-fixed paraffin-embedded (FFPE) tissue
blocks were retrieved and reviewed by the pathologist, who
was blinded to ethnicity and other personal characteristics.
The ER/PR status and HER2/neu status reported inpatient pathology reports were determined by immu-
nohistochemistry (IHC).
Immunohistochemical analysis
Formalin-fixed paraffin-embedded tissue sections were
mounted on superfrost slides and stained using appro-
priate positive and negative controls as we have de-
scribed previously [18,19].
The sections (5 μm) were de-paraffinized, rehydrated
and processed for antigen retrieval using Dako Antigen
Retrieval Solution. Tissue peroxidases were inactivated
by treatment with 3% H2O2 for 5 min, and the sections
pre-treated with antibody diluent solution containing 1%
BSA, followed by 40 min incubation at room temp-
erature with primary antibodies for ALCAM (1:40 dilu-
tion, Novocastra Laboratories). Labeling was accomplished
with biotinylated secondary antibodies and streptavidin-
HRP using Biotinylated Link Antibody kit (Dako North
America Inc, Carpinteria, CA), AEC substrate chromogen,
and counterstained with hematoxylin for 5 min. Sections
were mounted with aqueous media, examined using
Olympus AX70 microscope and images were recorded
with camera (Olympus U-CMAD3 DP70) and software
(Olympus DP70/DP30 BW, ver.02.0201.147). Negative
control tests were conducted with samples in the ab-
sence of primary antibody. Similarly, control paraffin
slides with known negative or positive expression
ALCAM were tested alongside of unknown samples.
Evaluation of immunohistochemistry
Stained tissue sections were independently examined in
a blinded fashion by two clinical pathologists, who were
blinded to clinical information and pathological pa-
rameters. ALCAM expression at intercellular junctions
(i.e. membranous) and in the cytoplasm was evaluated
separately. An immunoreactive score (IRS) based on
the percentage of positive cells and staining intensity
was applied. The percentage of positive cell scores
were assigned according to the following scale: 0: 0%; 1:
1-20%; 2: 21-50%; 3: 51-80%; 4: >80%. Staining intensity
was scored semi-quantitatively as follows: 0: none; 1: mild;
2: moderate; and 3: intense. A total score for each mem-
brane and cytoplasmic staining was then obtained (ran-
ging from 0 to 12). Results were summed up and divided
by the number of evaluation procedures to receive an
average.
Statistical analysis
Data analyses were performed using SPSS (SPSS Inc,
Chicago, IL, USA) and GraphPad Prism Software (version
5.0). Fisher’s exact or chi-square tests were used to evalu-
ate differences in clinico-pathological characteristics
between AA and CAU women and correlations between
expression of ALCAM (low or high) and clinic-pathological
Table 1 Clinical and pathological characteristics of AA
and CAU breast cancer in Atlanta
Characteristics CAU (n = 95) AA (n = 78) p value
n % n %
Age at diagnosis 0.99
≤ 50 years 29 30.5 23 29.5
> 50 years 66 69.5 55 70.5
Histological type 0.003*
Ductal 74 77.8 76 97.4
Lobular 7 7.4 2 2.6
Ductal/Lobular 7 7.4 0
Missing 7 7.4
Histological grade 0.069
G1 29 30.5 16 20.5
G2 44 46.3 29 37.2
G3 17 17.9 24 30.8
Missing 5 5.3 9 11.5
Tumor size 0.026*
T1 69 72.6 34 43.6
T2 15 15.8 20 25.6
T3-T4 6 6.3 7 9.0
Missing 5 5.3 17 21.8
Lymph node status 0.68
Negative 48 50.5 38 48.7
Positive 25 26.3 23 29.5
Missing 22 23.2 17 21.8
AJCC stage 0.65
I 40 42.1 28 35.9
II 22 23.2 18 23.1
III-IV 11 11.5 12 15.4
Missing 22 23.2 20 25.6
ER status 0.001*
Negative 15 15.8 30 38.5
Positive 70 73.7 45 57.7
Missing 10 10.5 3 3.8
PR status 0.081
Negative 28 29.5 34 43.6
Positive 57 60 41 52.6
Missing 10 10.5 3 3.8
HER2-neu status 0.13
Negative 67 70.5 65 83.4
Positive 19 20 9 11.5
Missing 9 9.5 4 5.1
Table 1 Clinical and pathological characteristics of AA
and CAU breast cancer in Atlanta (Continued)
Triple negative 0.0008*
Yes 10 10.5 25 32.0
No 74 77.9 51 65.4
Missing 11 11.6 2 2.6
AJCC: American Joint Committee on Cancer; CAU: Caucasian; AA: African-American;
ER/PR: estrogen/progesterone receptor; HER2-NEU: human epidermal growth
receptor 2. *Age-adjusted.
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ethnicity, age, histological grade, tumor size, lymph node
status, ER/PR status and HER2-neu status was determined
by logistic regression with multivariate analysis. Odds ratio
(OR), and 95% confidence interval (CI) were also calcu-
lated. Two-sided p values were calculated. Differences and
correlations were considered significant if p value was <
0.05 (*), <0.01 (**) and <0.001 (***).
Results
Clinico-pathological characteristics of AA and CAU breast
cancer
Clinico-pathological characteristics of breast cancer pa-
tients are summarized in Table 1. Of 173 breast cancer
patients, there were 95 CAU and 78 AA women. In both
ethnic groups, there was relatively equal distribution of age
at diagnosis [diagnosed with breast cancer at age greater
than 50 years (CAU 69.5% vs. AA 70.5%; p = 0.99)]. The
predominant histological type was ductal adenocarcinoma
(CAU 77.8% vs. AA 97.4%; p = 0.003), and there was no
statistical difference in histological grade between the two
ethnic groups (p = 0.069). AA women presented with a
significantly lower proportion of smaller size tumors
(T1) compared to CAU women (AA 43.6% vs. CAU
72.6%; p = 0.026). However, no statistical difference was
found in clinical staging or nodal status at presentation
between the two ethnic groups (Table 1). Breast cancers in
AA women were ER Negative in larger proportions
(38.5%) compared to the CAU patients (15.8%, p = 0.001),
whereas there was no difference in PR expression (p =
0.081). More than three fourths of all patients were HER-2
negative, and there was no significant difference between
the AA and CAU patients (p = 0.13). One third of all AA
patients showed negative markers for ER, PR and HER-2
neu (triple negative), compared to only 10.5% of CAU
patients (p = 0.0008).
Overall ALCAM expression in AA and CAU breast cancer
tumors
Immunohistochemical analysis of ALCAM was performed
to determine its subcellular localization and level of
expresssion in primary breast tumors of AA and CAU
women. ALCAM was locliazed to intercellualr junc-
tions/membrane and the cytoplasm. The stain intensity
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tive (very strong), 2+ positive (clear staining but not as
strong as 3+), 1+ positive (some lighter staining), and
negative (no staining) (Figure 1). We developed a Im-
munoreactive Score (IRS) by combining both intensity
of IHC and percentage of ALCAM-positive tumor
cells. ALCAM expression in CAU and AA breast can-
cer tissue is listed in Table 2. There were significant
differences in membrane ALCAM expression between
the two ethnic groups, with a higher proportion of
higher scores (IRS 8–12) in CAU as compared to AA
(CAU 85.2% vs. AA 53.8%; p < 0.0001) (Figure 2). Not-
ably, there was a higher proportion of negative mem-
branous staining in AA patients as compared to CAU
patients (AA 16.7% vs. CAU 3.2%). However, there was
no difference in the degree of cytoplasmic ALCAM
staining between the two groups (p = 0.06).
ALCAM and clinical characteristics of AA and CAU breast
cancer
We examined membranous ALCAM in the context of
patient characteristics and tumor pathology. Poorly
differentiated tumors showed lower intensity membranous
staining (IRS 0–7) (AA: p = 0.04; CAU: p = 0.02) (Table 3).
An increase in membranous ALCAM expression associ-
ated with positive ER status (AA: p = 0.0004; CAU: p =
0.0015) and PR status (AA: p = 0.002; CAU: p = 0.034) in
both ethnic groups. Most notably triple negative tumorsFigure 1 The intensity of immunohistochemistry staining with ALCAM
cytoplasmic staining. (b) C2+ positive: clear staining but the intensity is no
(d) Negative: no staining. (e) M3+ positive: intensity is very strong in mem
as strong as M3+. (g) M1+ positive: some light membranous staining. (h) N(TN: ER, PR, and HER-2 neu negative) showed signifi-
cantly lower intensity membranous staining (IRS 0–7) as
compared to tumors that were not triple negative in both
ethnic groups (AA; p = 0.0002; CAU; p = 0.0006). There
was no significant correlation with the membranous pat-
tern of staining and age of the patient, histological tumor
type, tumor size, lymph node status or HER2-neu status
in either ethnic group.
Multivariable analysis of ALCAM expression with
ethnicity
Since loss of ALCAM function is a bad prognostic marker
in breast cancer, we examined which factors would con-
tribute most significantly to its expression. We built a mul-
tivariable logistic regression model to include basal-like
subtype, ethnicity and four additional covariates (age,
histological grade, tumor size, lymph node status). Table 4
demonstrates that ethnicity contributed significantly to
ALCAM expression after adjustment for the other
covariates. Compared to CAU, the AA tumors were about
4-times more likely to have low ALCAM expression (p =
0.003), after accounting for basal-like status and the
other four variables. Basal-like status was associated with
ALCAM expression (p = 0.01) however in this model, age
(under or above 50 years), histological grade (poorly
and well-moderately), tumor size [large (>2 cm) and small
(≤2 cm)], lymph node status, did not contribute to
ALCAM expression.in breast cancer tissue. (a) C3+ positive: intensity is very strong in
t as strong as c3+. (c) C1+ positive: some light cytoplasmic staining.
branous staining. (f) M2+ positive: clear staining but the intensity is not
egative: no staining. Original magnification, x400.
Table 2 ALCAM expression in AA and CAU breast cancer
Ethnicity Membranous staining n (%) p value Cytoplasmic staining n (%) p
valueNegative staining IRS 1-7 IRS 8-12 IRS 1-7 IRS 8-12
CAU (n = 95) 3(3.2) 11(11.6) 81(85.2) <0.0001* 29(30.5) 66(69.5) 0.06
AA (n = 78) 13(16.7) 23(29.5) 42(53.8) 35(44.9) 43(55.1)
CAU: Caucasian, AA: African-American, IRS: immunoreactive score, *Age-adjusted.
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ALCAM is emerging as an important molecule in cancer
due to its consistent differentiation of aggressive pheno-
types, prognosis and response to therapy [19,23,26]. The
goal of this study was to define for the first time the role
of ALCAM in the ethnic disparity of breast cancer in
the US. The major findings are that ALCAM expression at
the critically important intercellular junctions of primary
breast cancer tumors is markedly lower in AA women
compared to CAU women, regardless of age, histological
grade, tumor size and lymph node involvement, ER/PR
and HER2-neu status. These findings suggest that ALCAM
may dominantly contribute to the aggressive behavior of
breast cancer among AA women.
Breast cancer in AA women is characterized by higher
grade, later stage at diagnosis and worse survival rate
[2,27]. Variations in tumor biology at several stages of
the disease process likely contribute to this disparity.
Molecular and genetic profiling has revealed inter- and
intra-ethnic heterogeneity of breast cancer with varied
prognoses and responses to therapy [28-30]. Luminal
tumors have the most favorable outcome while Her2-
overexpressing and basal-like (triple-negative, TN)Figure 2 Distribution of membranous ALCAM expression in AA
and CAU breast cancer patients. ALCAM levels were determined
by immunohistochemistry (IHC) according to the immunoreactive
Score (IRS) by combining both intensity of IHC and percentage of
tumor cells stained as stated in materials and methods. The x-axis
indicates the Membranous ALCAM Immunoreactive score (IRS).
The range of IRS is from 0 (negative staining) to 12. The y-axis indicates
the frequency of cases.tumors have the worst prognoses [31-34]. Triple-negative
tumors are aggressive with a peak risk of recurrence
within three years of diagnosis [35,36]. This aggressive
subtype is more common in AA women [31,37,38], and
contributes to the poor prognosis in young AA women
[31]. We confirmed the major ethnic-related histological
and molecular phenotypes of breast cancer in our two
populations, which provided an important validation of
the ethnic categorization of patients, clinicopathological
evaluations and the data analyses we used in our study
(Table 1). Even after accounting for this major confounder
(basal-like subtype), ALCAM expression at intercellular
tumor junctions was significantly lower among the AA
women with breast cancer (Table 4). These findings re-
affirm the prognostic status of ALCAM in breast cancer.
Ethnic differences in ALCAM expression were found
when tumors were characterized by histological grade,
size and lymph node involvement. ALCAM is thought
to contribute to events that influence the transition
of homotypic behavior in tumor masses to heterotypic
interactions with surrounding cell types. This process
is driven in part by proteolytic cleavage of membrane
bound ALCAM by ADAM/TACE and its subsequent
loss from intercellular tumor junctions [39]. Cytoplasmic
overexpression of ALCAM is prognostically relevant in
breast cancer [22]. The mechanism responsible for this as-
sociation of higher cytoplasmic ALCAM levels with a
more aggressive course of the disease is not fully ad-
dressed. In the current study, we did not find a significant
association of cytoplasmic ALCAM expression with ethni-
city. We reported recently that ALCAM dominantly influ-
ences the adhesive phenotypes of breast cancer cells in the
pulmonary vasculature, a process that influences metasta-
sis to the lung. MDA-MB-231 cells, which cannot
metastasize to distant sites when injected into the mam-
mary fat pad of athymic nude mice [40,41] formed large
ALCAM-mediated homotypic intravascular cell clusters
in an isolated perfuse rat lung model. Conversely,
ALCAM-negative MDA-MB-435 cells that spontaneously
form distant metastasis [40-43] formed similar clusters
only after ectopic ALCAM transfer [44,45]. In this
study, we found that most AA tumors had low or
complete loss of ALCAM expression at intercellular
junctions regardless of the basal-like status, level of differ-
entiation, tumor size, lymph node involvement and age
(Table 4). Compared to CAU tumors, The AA are about 4
Table 3 Membranous ALCAM expression and clinical and histological tumor characteristics of AA and CAU
breast cancer
Membranous ALCAM (n,%) in Caucasian Membranous ALCAM (n,%) in African American
IRS 0-7 IRS 8-12 p value IRS 0-7 IRS 8-12 p value
Age in years 0.41 0.65
≤50 3(3.1) 26(27.4) 10(12.8) 13(16.7)
>50 11(11.6) 55(57.9) 27(34.6) 28(35.9)
Histological Type 0.38 0.93
IDC 10(11.4) 64(72.7) 36(46.2) 40(51.3)
ILC 0(0) 7(8) 1(1.3) 1(1.3)
IDC&ILC 1(1.1) 6(6.8) 0(0) 0(0)
Histological Grade 0.02* 0.04*
G1 3(3.3) 26(28.9) 5(7.2) 11(15.9)
G2 3(3.3) 41(45.6) 11(15.9) 18(26.1)
G3 6(6.7) 11(12.2) 16(23.2) 8(11.6)
Tumor size 0.71 0.82
T1 9(10) 60(66.7) 15(24.6) 19(31.1)
T2 3(3.3) 12(13.3) 9(14.8) 11(18.0)
T3-T4 1(1.1) 5(5.5) 4(6.6) 3(4.9)
Lymph node status 0.95 0.44
Negative 6(8.2) 42(57.5) 16(26.2) 22(36.1)
Positive 3(4.1) 22(30.1) 12(19.7) 11(18)
ER status 0.0015* 0.0004*
Negative 7(8.2) 8(9.4) 21(28) 9(12)
Positive 6(7.1) 64(75.3) 13(17.3) 32(42.7)
PR status 0.034* 0.002*
Negative 8(8.9) 20(23.5) 22(29.3) 12(16)
Positive 5(5.9) 52(61.2) 12(16) 29(38.7)
HER2-neu status 0.14 0.096
Negative 12(14) 55(63.9) 31(41.9) 34(45.9)
Positive 1(1.2) 18(20.9) 2(2.7) 7(9.5)
Triple Negative 0.0006* 0.0002*
Yes 6(7.1) 4(4.8) 19(25) 6(7.9)
No 7(8.3) 67(79.8) 16(21.1) 35(46.1)
*Age-adjusted.
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0.003). ALCAM expression was high in virtually all
well-differentiated tumors in CAU women while nearly
one-third of tumors of the same level of differentiation
in AA women had low ALCAM. This discordance revealed
that well-differentiated tumors in AA women are equivalent
in number to poorly differentiated tumors in CAU women
with respect to ALCAM expression.
It is thought that the level of differentiation of breast
cancer tumors influences their overall aggressive pheno-
type. A lower proportion of breast cancer among the AAwomen in our study was well differentiated as expected
(CAU 76.8% vs AA 57.7%). In addition, we uncovered
a new source of biological variation (i.e. reducing ALCAM
expression), which suggests that well differentiated tumors
may adopt a more aggressive phenotype uniquely among
AA women. This assertion is based on results showing
low ALCAM expression in significantly higher number of
well differentiated tumors in this patient population.
Overall, our data suggests that compared to CAU women,
breast cancer tumors of equivalent size and histological
grade in AA women are more likely to lose homotypic
Table 4 Multivariable logistic regression analysis of the









AA 37 (72.55) 41 (33.61) 4.28(1.64- 11.15) 0.003
CAU 14 (27.45) 81 (66.39) Reference
Age in years
≤50 13 (25.49) 39 (31.97) 0.69 (0.24- 1.99) 0.49
>50 38 (74.51) 83 (68.03) Reference
Histological grade
Poor 22 (50.00) 19 (16.52) 2.10(0.60- 7.34) 0.25
Well-moderately 22 (50.00) 96 (83.48) Reference
Tumor size
Large (>2 cm) 17 (41.46) 31 (28.18) 0.62( 0.20-1.88) 0.39
Small (≤2 cm) 24 (58.54) 79 (71.82) Reference
Lymph node
Positive 15 (40.54) 33 (34.02) 1.62( 0.58- 4.54) 0.36
Negative 22 (59.46) 64 (65.98) Reference
Basal-like (TN)
Yes 25 (51.02) 10 (8.85) 5.59(1.46- 21.50) 0.01
No 24 (48.98) 103 (91.15) Reference
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their metastatic potential.
Conclusions
ALCAM expression at intercellular tumor junctions
correlates with tumor grade, ER status, PR status and
triple-negative tumor status in breast cancer patients.
Down-regulation of ALCAM is more severe in AA women
than in CAU women even when the tumors have identical
characteristics, such as histological grade, tumor size and
lymph involvement. Lower ALCAM expression may con-
tribute to the aggressive phenotype of breast cancer among
AA women.
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